{"url_path":"/sec/bcda/8-k/2026-05-21/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 **         **Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/925741/0001437749-26-017994-index.html","accession_number":"0001437749-26-017994","cik":"0000925741","ticker":"BCDA","issuer_name":"BioCardia, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/925741/0001437749-26-017994-index.html","primary_entity_key":"0000925741","primary_entity_name":"BioCardia, Inc."},"word_count":291,"has_tables":true,"body_markdown":"**Item 7.01**         **Regulation FD Disclosure.**\n\n \n\nOn May 21, 2026, BioCardia, Inc. issued a press release announcing the oral presentation of the results of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial (CardiAMP CMI) preliminary open label cohort at Euro PCR, a leading interventional cardiovascular medicine conference held in Paris. The presentation was made by Dr. Amish Raval, M.D., Professor of Medicine at University of Wisconsin School of Medicine and Public Health.\n\n \n\nThe results presented by Dr. Raval, on behalf of the CardiAMP CMI Investigators, showed that the minimally invasive CardiAMP Cell Therapy procedure was well tolerated with no treatment emergent major adverse cardiac events and patients demonstrated positive clinical outcomes including increased exercise tolerance and reduced frequency of angina episodes with the autologous cell therapy up through two years follow-up. Prior to treatment, all patients were on guideline-directed medical therapy and had received all available percutaneous and/or surgical options as appropriate for their medical condition. Patients experienced increased exercise tolerance, improving by an average of 179 seconds, which persisted for the two-year study follow-up. Angina episodes were reduced by an average of 82% by six-months after treatment.\n\n \n\nA copy of the press release is attached hereto as Exhibit 99.1 to this current report on Form 8-K.\n\n \n\nThe information furnished pursuant to this Item 7.01, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section, nor shall it be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly set forth by specific reference in such filing."}